Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award: Doctoral Foreign Study Award (DFSA)

Direct Payment

$105,000.00

The role of interferons in the risk of stroke and dementia

FY 2022-23

Summary
Stroke is most often caused by blood clots impeding part of brain's circulation. Despite best available treatments, people who survive a stroke remain at high risk of a second event. People with brain vessel disease (either with or without prior stroke) also have a higher risk of developing dementia. There is, therefore, a pressing need to identify novel strategies to better prevent stroke and dementia. We built an innovative project to determine whether inflammation, an emerging contributor to vascular disease, may be a viable target to reduce the risk of stroke and dementia. We are especially interested in the role of key components of inflammation, called interferons, in the risk of stroke and dementia. Our project has two phases. In the first phase, we will use data collected as part of a prior study led in Scotland, called the Generation Scotland cohort. This study included over 20,000 people who agreed to make a blood draw when they were recruited. Participants were followed for over 10 years to assess whether they had a new diagnosis of stroke or dementia. We will use a small portion of participants' initial blood sample to measure circulating levels of interferons. This will allow us to determine whether higher levels of interferons at baseline are observed in people who later have a stroke or dementia. In the second phase, we will use a novel powerful method, called Mendelian randomization. This technique uses variations that naturally occur in genes (called polymorphisms) that increase one's levels of interferons. By assessing whether these polymorphisms are also more frequent in people who suffer a stroke or dementia, we will be able to determine whether higher interferon levels truly cause stroke. We will use data from two large studies, called MEGASTROKE and UK Biobank, to complete these analyses. Our research will help identify novel targets that may help reduce the risk of stroke and dementia in the general population.
Program
Doctoral Award: Doctoral Foreign Study Award (DFSA)
Location
United Kingdom
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
474039
Name
Rioux Bastien
Country
United Kingdom
Orgtype
Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Doctoral Research Awards - A
Projecttitle
The role of interferons in the risk of stroke and dementia
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award: Doctoral Foreign Study Award (DFSA)
Keyworddelim
Atherosclerosis; Case-Control; Cohort; Cytokines; Genetics; Inflammation; Interferons; Mendelian Randomization; Small Vessel Disease; Stroke
Abstract
Stroke is most often caused by blood clots impeding part of brain's circulation. Despite best available treatments, people who survive a stroke remain at high risk of a second event. People with brain vessel disease (either with or without prior stroke) also have a higher risk of developing dementia. There is, therefore, a pressing need to identify novel strategies to better prevent stroke and dementia. We built an innovative project to determine whether inflammation, an emerging contributor to vascular disease, may be a viable target to reduce the risk of stroke and dementia. We are especially interested in the role of key components of inflammation, called interferons, in the risk of stroke and dementia. Our project has two phases. In the first phase, we will use data collected as part of a prior study led in Scotland, called the Generation Scotland cohort. This study included over 20,000 people who agreed to make a blood draw when they were recruited. Participants were followed for over 10 years to assess whether they had a new diagnosis of stroke or dementia. We will use a small portion of participants' initial blood sample to measure circulating levels of interferons. This will allow us to determine whether higher levels of interferons at baseline are observed in people who later have a stroke or dementia. In the second phase, we will use a novel powerful method, called Mendelian randomization. This technique uses variations that naturally occur in genes (called polymorphisms) that increase one's levels of interferons. By assessing whether these polymorphisms are also more frequent in people who suffer a stroke or dementia, we will be able to determine whether higher interferon levels truly cause stroke. We will use data from two large studies, called MEGASTROKE and UK Biobank, to complete these analyses. Our research will help identify novel targets that may help reduce the risk of stroke and dementia in the general population.
Competitiondate
202210
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Rioux, Bastien
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~